Clinical Trial Update: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating remibrutinib versus dupilumab at early timepoints in adults with chronic spontaneous urticaria inadequately controlled by seco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Dupilumab (dupilumab)
• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria (CSU) | Phase 3 | Status: RECRUITING